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Abstract
Background: Up to 50 % of HIV-infected persons in sub-Saharan Africa are lost from care between HIV diagnosis
and antiretroviral therapy (ART) initiation. Structural barriers, including cost of transportation to clinic and poor
communication systems, are major contributors.
Methods: We conducted a prospective, pragmatic, before-and-after clinical trial to evaluate a combination mobile
health and transportation reimbursement intervention to improve care at a publicly operated HIV clinic in Uganda.
Patients undergoing CD4 count testing were enrolled, and clinicians selected a result threshold that would prompt early
return for ART initiation or further care. Participants enrolled in the pre-intervention period (January – August 2012) served
as a control group. Participants in the intervention period (September 2012 – November 2013) were randomized
to receive daily short message service (SMS) messages for up to seven days in one of three formats: 1) messages
reporting an abnormal result directly, 2) personal identification number-protected messages reporting an abnormal
result, or 3) messages reading “ABCDEFG” to confidentially convey an abnormal result. Participants returning within seven
days of their first message received transportation reimbursements (about $6USD). Our primary outcomes of interest were
time to return to clinic and time to ART initiation.
Results: There were 45 participants in the pre-intervention period and 138 participants in the intervention period (46, 49,
and 43 in the direct, PIN, and coded groups, respectively) with low CD4 count results. Median time to clinic return was 33
days (IQR 11–49) in the pre-intervention period and 6 days (IQR 3–16) in the intervention period (P < 0.001); and median
time to ART initiation was 47 days (IQR 11–75) versus 12 days (IQR 5–19), (P < 0.001). In multivariable models, participants
in the intervention period had earlier return to clinic (AHR 2.32, 95 %CI 1.53 to 3.51) and earlier time to ART initiation
(AHR 2.27, 95 %CI 1.38 to 3.72). All three randomized message formats improved time to return to clinic and time to
ART initiation (P < 0.01 for all comparisons versus the pre-intervention period).
Conclusions: A combination of an SMS laboratory result communication system and transportation reimbursements
significantly decreased time to clinic return and time to ART initiation after abnormal CD4 test results.
Trial registrations: Clinicaltrials.gov NCT01579214, approved 13 April 2012.
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Background
Despite expanded access to antiretroviral therapy (ART)
[1], programs in resource-limited settings continue to
document high mortality rates during early stages of
disease [2–4]. An important contributor to poor outcomes
is suboptimal retention of patients between HIV diagnosis
and ART initiation [5], when mortality rates are highest
[6, 7], and approximately 20–50 % of patients are lost to
care [8–10].
Structural barriers to care in resource-limited settings,
including transportation costs and absence of commu-
nication between providers and patients, are major
contributors to poor linkage [11–14]. Communication
of critical clinical information to patients in the com-
munity represents a particular challenge. For example,
reporting and responding to abnormal clinical investi-
gations typically requires patients to return for a re-
peat clinical visit, which comes at significant cost and
time away from economic activity for patients [15]. In
cases of an indication for ART initiation, treatment
failure, severe treatment complications, or evidence of
opportunistic infection, such reporting and intervention
delays result in adverse outcomes and/or compromise
future treatment options.
Scalable interventions that mitigate structural bar-
riers to clinical care in resource-limited settings are ur-
gently needed. Mobile health (mHealth) applications
hold promise in this area by leveraging existing cellular
phone infrastructure to improve patient-provider com-
munication and prioritize care delivery for those most
in need. Cellular phone coverage in sub-Saharan Africa
increased from 5 to 70 % of the population during the
past decade, while personal subscriptions increased from
16 to 380 million [16, 17]. While short message service
(SMS) reminders have been shown to improve ARTadher-
ence [18, 19], there has been limited data to evaluate
the efficacy of mHealth interventions to improve clin-
ical care. We previously reported results of a survey to
assess the acceptability of an SMS-based laboratory re-
sults notification system to communicate abnormal la-
boratory results to patients at a publicly operated HIV
clinic in rural, southwestern Uganda [20]. We found
that acceptance was nearly 100 % and that benefits of
improved patient-provider communication outweighed
potential concerns about breaches of confidentiality.
We now report results of a follow-up intervention trial
to evaluate an mHealth laboratory result notification
system coupled with transportation stipends to improve
care for people living with HIV undergoing critical la-
boratory tests in rural Uganda. We hypothesized that
the mHealth application coupled with transportation
reimbursements would reduce time to clinic return and
time to ART initiation for patients with low CD4 count
results.
Methods
Study population and eligibility criteria
Study participants were enrolled from a publicly oper-
ated President’s Emergency Plan for HIV/AIDS Relief
(PEPFAR)-supported HIV clinic at the Mbarara Regional
Referral Hospital in Mbarara, Uganda. Eligibility criteria
included: a) current enrollment at the adult HIV clinic,
b) self-reported access to a cellular phone, whether per-
sonal or shared, c) residence in a district immediately
surrounding the clinic (Ibanda, Isingiro, Kirihura, Mbarara,
or Ntungamo Districts), and d) undergoing a CD4+ T-
lymphocyte (CD4) test determined by the ordering
clinician to be of critical importance (that is, a test for
which an abnormally low result would ideally prompt
early return to care). Clinicians selected the abnormal
CD4 result threshold on the day the laboratory test
was ordered. The threshold was meant to specify a result
below which an early return to clinic would be requested
for clinical evaluation. Potential participants could be ART-
naïve or on ART (with concern for treatment failure). We
did not include viral load testing as an inclusion criterion
because it is not available free of charge at the clinic and
was rarely performed outside of research activities.
Intervention development
The intervention was developed based on a conceptual
framework developed through pre-study mixed-methods
research. Pre-intervention interviews with patients and
providers at the clinic revealed two major barriers to clinic
return after abnormal test results at this site: 1) lack of
communication between staff and patients outside of clin-
ical visits, which limited patient decision-making capacity
[20], and 2) inadequate access to financial support for
costs of transportation to clinic [14, 15, 21]. Based on this
empirical evidence, we hypothesized that an effective
intervention to improve response to abnormal test results
would require both improved clinical communication to
patients and financial reimbursement to overcome eco-
nomic barriers to care. After the basic features of the
intervention were selected, we implemented a co-creation
model involving researchers, programmers, clinicians, and
patients in key considerations about the SMS intervention
[22], including 1) optimizing message formats to maximize
confidentiality and privacy, 2) selection of the frequency,
duration, and timing of messages, 3) language preferences,
and 4) inclusion of an option to respond to messages for
confirmation of receipt. We pilot tested the system with
both study staff and clinicians to optimize interpretation,
readability, and ease of use.
Pre-intervention study group and procedures
We initially considered a fully randomized control trial,
including a control group without a notification SMS
message. We decided against this for two reasons. First,
Siedner et al. BMC Medicine  (2015) 13:160 Page 2 of 11
in a preliminary acceptability study at the clinic, we
found that 100 % of surveyed participants desired cellular
phone communication about their laboratory test results
[20]. Second, ethical concerns were raised about the safety
of a control arm in which participants who do not receive
SMS messages could misinterpret lack of an SMS message
as positive information about their test results. Thus, in
place of a fully randomized trial design, we prospectively
collected data on eligible participants in two stages: 1) a
pre-intervention period (January – August 2012) and 2)
an intervention stage (September 2012 – November 2013),
as has been done with a similar clinical intervention
targeting abnormal CD4 count results [23]. During the
pre-intervention stage, clinicians completed eligibility
forms for each participant, including confirmation of
access to a cellular phone, district of residence, and
selection of the abnormal result threshold for the CD4
test, which would prompt a request for an early return to
clinic. Standard clinical forms were completed to collect
data on sociodemographic and clinical characteristics. We
also collected data on the laboratory result and result date,
time from laboratory result to clinic return, and for ART-
naïve participants, time to ART initiation.
Intervention study group and procedures
During the intervention period, clinicians used eligibility
criteria identical to those used during the pre-intervention
period, including selection of an abnormal CD4 count
threshold to trigger the SMS and transportation reim-
bursement intervention. We discussed message design
with study clinicians during the intervention design
phase. They requested an individualized determination
of abnormal test results over a standardized method,
largely to allow enrollment of patients already on therapy
who were considered to be at risk for treatment failure.
Similarly, clinicians scheduled the next clinic appointment
prior to study enrollment during both study periods.
Eligible participants completed written informed consent
to receive health messages on their phone, completed a
baseline structured survey to collect SMS scheduling
preferences, and were given a brief instructional session to
describe possible messages and select a personal identifi-
cation number (PIN) to open messages.
Those with a CD4 test result above the clinician-
specified threshold (that is, a “normal” laboratory result)
received a single SMS message stating that their test result
was within the normal range and that they should return
to clinic as scheduled. For participants with a CD4 test re-
sult below the stated threshold (an abnormal result), study
staff used the randomization module within the Research
Electronic Data Capture (REDCap [24]) study database to
assign participants to an intervention arm. Participants
were randomized in a 1:1:1 design to receive one of the
following three SMS message formats: 1) an unprotected
SMS indicating an abnormal test result and that they
should return to clinic as soon as possible: “This is an im-
portant message from your doctor. You had an abnormal
test result. You should return to clinic as soon as possible.”
(direct message). This message was meant to maximize
clarity. 2) The use of a PIN-protected SMS message, which
displayed an identical message as the direct message only
after successful entry of the correct PIN code (PIN mes-
sage). The PIN code was intended to augment message
privacy. 3) The use of a message reading “ABCDEFG”
(coded message). This message was coded without men-
tion of clinical information to maximize confidentiality,
but not require the participant to remember and enter a
PIN code. Research assistants explained to participants on
enrollment that the message indicated an abnormal test
result that should prompt early return to clinic.
Messages were scheduled and initiated with CommCare
(Dimagi, Inc., Cambridge, MA, USA), a web-based mobile
health application. Participants could receive up to seven
daily messages at preferred days of the week and times
of day (6AM, 9AM, 5PM, or 9PM) that were selected
by participants during the baseline survey. On the date
and time of each scheduled message, CommCare sent a
web-based automated prompt with the content of the
message to a Ugandan-based telecommunications com-
pany (Yo! Voice Solutions and Software Development,
Kampala, Uganda), which relayed an automated SMS to
the indicated phone number. The messages cost $0.02
each to send, and were paid for by the study. Participants
in the intervention period with a normal laboratory result
received a single message at the next preferred date and
time that was indicated on their enrollment scheduling
form. Participants in the intervention group received a
single abnormal result message daily, up to a maximum
of seven days after the abnormal result. Participants
who returned to clinic within seven days of the first abnor-
mal result message received a transportation reimburse-
ment stipend of 15,000 Ugandan shillings (approximately
6$USD, the average estimated cost for transportation to
clinic in the clinic catchment area). Participants with nor-
mal laboratory results or those presenting after seven days
from the first message were not eligible for transportation
reimbursement. There were no blinding procedures as
part of this study.
For both study groups, we recorded the date of clinic
return after an SMS message and, for the ART-naïve
participants, the date of ART initiation. To assess re-
ceipt and comprehension of the messages, research as-
sistants called participants in the intervention period
who did not return to clinic within 14 days (after deter-
mination of primary outcome success or failure). We
performed home-based tracking for participants with
abnormal laboratory results who did not return to clinic
by 28 days.
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Sample size determination and statistical analysis
In our initial protocol, our prespecified primary outcome
of interest was return to clinic within 7 days of an abnormal
test result notification. However, we noted during study
planning that the time from test result to first SMS trans-
mission varied by participant. For example, if a participant
selected only a single day to receive messages (for example,
Mondays only) and the laboratory result returned on the
following calendar day (Tuesday), the maximum time
period from laboratory result to receipt of the first message
was 7 days, which corresponded to a maximum period of
14 days from test result to clinic return to achieve the de-
sired outcome. To ensure unbiased outcome assessment
between study arms, we changed our primary outcome to:
return to clinic within 14 days of when the laboratory result
was received back at the clinic from the laboratory. The
study was powered to detect a difference in return time for
participants with abnormal results. Whereas the study was
initially powered based on assumptions about clinic return
with 7 days, we updated our sample size estimates with
the 14-day outcome using data from the pre-intervention
period. During the pre-intervention period, approximately
30 % of 45 participants with abnormal laboratory results
returned to clinic within 14 days. We planned to enroll 45
participants with abnormal laboratory results in each
intervention arm in order to have 80 % power to detect
a doubling in return rate (60 % clinic return rate within
14 days of abnormal laboratory result) between the pre-
intervention period and each of the intervention groups.
We conducted survival analyses and fit Cox proportional
hazards regression models to estimate differences between
study arms in: 1) time to return to clinic after an abnormal
result and 2) time to initiation of ART among ART-naïve
participants. Our primary predictors of interest were mes-
sage type (comparing each of the three message formats
with the control group) and study period (comparing the
control period with the intervention period). Models were
adjusted for known predictors of clinic retention in care
based on prior studies, including age, gender, district of
residence, education, and CD4 result [25]. Participants in
the intervention period who were tracked at home were al-
located as treatment failures for all study endpoints. For
time-to-event analyses, we right censored participants at
180 days who did not return to clinic by that time. Finally,
to estimate the impact of the intervention for those with
normal laboratory results, we also compared the proportion
of participants with normal results who returned to clinic
on or within 7 days of their scheduled return visit date. All
statistical analyses were performed with Stata Version 13
(StataCorp, College Station, TX, USA).
Ethical review
The study was reviewed and approved by the ethical re-
view committees of the Mbarara University of Science and
Technology (Reference Number: 1/7), Partners Healthcare
(Partners Reference Number: 2011P001538), and the
Ugandan National Council of Science and Technology
(Reference Number: IS 83). The trial and study protocol
were registered prior to study procedures at clinicaltrials.
gov (NCT01579214).
Results
Of 554 participants screened, 21 (6 %) were excluded
due to invalid laboratory results (n = 21). An additional
2 % (n = 12) were excluded from the intervention period
due to prior participation in the control period (Fig. 1).
Of the remaining 521 participants enrolled, 183 (35 %)
had abnormal CD4 results. There were 45 participants
in the pre-intervention period and 138 participants in
the post-intervention period (46, 49, and 43 participants
randomized to the direct, PIN, and coded message arms,
respectively). Characteristics of participants with abnormal
laboratory results are described in Table 1. Participants in
the pre-intervention period with abnormal results had
a higher median age and fewer were ART-naïve at the
time of enrollment. There were no meaningful differences
between participants in each of the three post-intervention
study groups (Additional file 1: Table S1). The number
of participants who were tracked at home at study day
28 (and allocated as failures to initiate ART) was 2 (4 %), 3
(6 %), and 1 (2 %), respectively, in the direct, PIN, and
coded arms.
The proportion of participants returning with 14 days,
the primary outcome of interest, was 27 % (12/45) in the
pre-intervention period and 67 % (93/138) in the interven-
tion period (P < 0.001, Table 2). Median time to clinic re-
turn was 33 days (IQR 11–49) in the pre-intervention
period and 6 days (IQR 3–16) in the intervention period,
whereas median time to ART initiation decreased from 47
days (IQR 11–77) to 13 days (5–22 days). In multivariable
models adjusted for age, gender, district of residence,
educational attainment, and CD4 result, participants in
the intervention period had shorter time to clinic return
(adjusted hazard ratio [AHR] = 2.32, 95 %CI 1.53–3.51,
P < 0.001, Table 3a, Fig. 2a) and shorter time to ART
initiation (AHR = 2.26, 95 %CI 1.38–3.72, P = 0.001,
Table 3b, Fig. 2b).
All three message formats outperformed the pre-
intervention period. Median days to clinic return after
abnormal results was 4, 11, and 6 days in the direct, PIN,
and coded message groups, respectively (P < 0.010 for all
comparisons by log-rank testing versus the control arm);
and median time to ART initiation was 8 (P = 0.002), 15
(P = 0.016), and 15 days (P < 0.001). All comparisons
between the pre-intervention period and each individ-
ual message format remained statistically significant in
multivariable analyses adjusted for sociodemographic
and clinical factors (Table 3a,b, Fig. 2a,b). There were
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Table 1 Characteristics of study participants with abnormal CD4+ T-lymphocyte results
Pre-intervention period Intervention period P-value
(No SMS message) (SMS + transportation reimbursement)
(n = 45) (n = 138)
Female gender (n, %) 19 (42) 75 (54) 0.16
Age (median, IQR) 38 (31 – 44) 30 (25 – 38) <0.001
Education (n, %) 0.71
<Primary 3 (8) 12 (9)
Any primary 16 (42) 71 (51)
Any secondary 12 (32) 37 (27)
>Secondary 7 (18) 18 (13)
ART-naïve (n, %) 26 (58) 110 (80) <0.001
Mbarara resident (n, %) 32 (71) 83 (60) 0.19
Days from enrollment until laboratory result, median (IQR) 11 (8 – 19) 10 (8-15) 0.32
Clinician-specified abnormal CD4 result threshold, median (IQR) 350 (250 – 350) 350 (350 – 350) <0.001
CD4 result, median (IQR) 185 (106 – 262) 225 (110 – 293) 0.29
SMS: short message service text message
PIN: personal identification number
IQR: interquartile range
ART: antiretroviral therapy
Fig. 1 Study flowchart for a combination intervention to improve HIV linkage to care in rural Uganda. Participants in the pre-intervention period
served as a control group. Participants in the intervention period with CD4 count below a clinician-selected threshold were randomized to receive
one of three short message service (SMS) text messages to inform them of abnormal laboratory results: 1) a direct message which stated that test
results were abnormal and they should return to clinic, 2) a personal identification number (PIN)-protected message that was otherwise identical
to the direct message, and 3) a coded message reading “ABCDEFG” to deliver an abnormal result message confidentially. Those who returned to
clinic within seven days received a transportation incentive
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no significant differences between message groups in
the proportion that returned within 14 days (P = 0.09),
the proportion that returned before their scheduled
visits (P =0.96), or the proportion that initiated ART
within 14 days (P = 0.32). Lastly, among those with
normal results, a greater proportion who received an
SMS message returned within 7 days of their scheduled
return date (73 versus 62 %, P = 0.044, Additional file 2:
Table S2). No participants died during the study and no
other adverse events related to the study were reported.
Discussion
A combination of an SMS-based laboratory results noti-
fication system coupled with transportation reimburse-
ments substantially shortened time of return to care and
time to ART initiation following abnormal CD4 count
results among patients at a publicly operated clinic in rural,
southwestern Uganda. While the primary intervention was
non-randomized, the effect size was large in all intervention
period subgroups, and a benefit was detected independent
of CD4 count, age, gender, home district, and educational
attainment. These data from a prototypical, government-
operated, PEPFAR-supported clinic in a rural, resource-
limited setting in sub-Saharan Africa offer a promising
strategy to combat widespread patient attrition during
early stages of HIV care in the region.
Our study adds to a small list of proposed strategies
for improving timely return to HIV care in similar settings.
The most promising of these has been adoption of point-
of-care CD4 count testing. A study in Mozambique with a
similar before-and-after comparative effectiveness design
showed an approximately 50 % reduction in loss to follow-
up and a comparable decrease in ART initiation time from
48 to 20 days with the use of point-of-care CD4 count
testing [23]. However, a second retrospective analysis of
the impact of point-of-care testing on ART initiation at
a clinic in South Africa failed to demonstrate improved
return times in a non-research setting [26]. An important
comparative advantage of point-of-care CD4 testing over
the current intervention is the ability to streamline ART
initiation without the cost or delay associated with add-
itional clinic visits. While not evaluated in our study,
similar SMS-based notification programs have previously
been shown to include secondary benefits, including the
potential to improve patient-staff communication and per-
ceptions of quality of care [27–29]. Preliminary evidence
of this effect was suggested by the earlier return times
among study participants with abnormal laboratory re-
sults, and the higher proportion of participants with
normal laboratory results who returned within seven
days of their scheduled appointment, although the latter
effect could also be the result of other temporal changes.
Table 2 Crude outcomes by study group
Time to clinic return Pre-intervention
period (No SMS
message)
Intervention period (SMS +
transportation
reimbursement)
Direct SMS
message
group
PIN SMS
message
group
Coded SMS
message
group
(n = 45) (n = 138) P-value* (n = 46) (n = 49) (n = 43)
Days from abnormal laboratory
result to clinic return, median (IQR)
33 (11 – 49) 6 (3 – 16) <0.001 4 (2 – 13) 11 (4 – 18) 6 (3 – 15)
Proportion returned within 14 days
of abnormal result (n, %)
12/45 (27) 93/138 (67) <0.001 36/46 (78) 28/49 (57) 29 /43(67)
Proportion returned within 28 days
of abnormal result (n, %)
22/45 (49) 128/138 (93) <0.001 43/46 (94) 43/49 (89) 42/43 (98)
Proportion returned before
scheduled visit (n, %)
11/45 (24) 96/137 (70) <0.001 33/46 (72) 34/49 (69) 29 /42 (69)
Time to ART initiation (ART-naïve
only)
Pre-intervention
period (No SMS
message)
Intervention period (SMS +
transportation
reimbursement)
P-value* Direct SMS
message
group
PIN SMS
message
group
Coded SMS
message
group
(n = 45) (n = 138) (n = 37) (n = 39) (n = 34)
Days from abnormal laboratory
result to ART initiation, median
(IQR)
47 (11 – 77) 13 (5 – 22) <0.001 8 (3 – 25) 15 (7 – 24) 15 (4 – 19)
Participants initiating ART within 14
days of abnormal result (n, %)
7/26 (27) 57/110 (52) 0.06 24 (62) 17 (46) 16 (47)
Participants initiating ART within 28
days of abnormal result (n, %)
8/26 (31) 89/110 (81%) <0.001 30/39 (77) 30/37 (81) 29/34 (85)
*P-values for comparisons between the pre-intervention and post-intervention periods, using log-rank testing for continuous time to return outcomes and
chi-squared testing for categorical outcomes
IQR: interquartile range
SMS: short message service text message
ART: antiretroviral therapy
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Table 3 Univariable and multivariable Cox proportional hazards estimates demonstrating hazard of time to clinic return (A) and time to ART initiation (B)
A. Outcome: Time to return to clinic after an abnormal CD4+ T-lymphocyte result
Univariable estimate Multivariable estimate
Characteristic HR (95 %CI) P-value AHR (95 %CI) P-value
Age (each year) 0.99 (0.98 – 1.01) 0.435 1.02 (1.00 – 1.03) 0.043
Female gender 0.98 (0.73 – 1.32) 0.885 0.94 (0.68 – 1.28) 0.673
Educational attainment (Ref: primary or less) 1.13 (0.84 – 1.54) 0.419 1.00 (0.73 – 1.38) 0.994
Mbarara district resident 1.17 (0.86 – 1.59) 0.323 1.33 (0.96 – 1.85) 0.082
ART-naïve 1.56 (1.10 – 2.21) 0.011 1.48 (1.00 – 2.19) 0.051
CD4 result (each 100 cells) 0.87 (0.75 – 1.01) 0.062 0.80 (0.69 – 0.93) 0.004
Study period
Control (no message) REF – REF –
Intervention (any message) 2.17 (1.53 – 3.09) <0.001 2.32 (1.53 – 3.51) <0.001
Study group
Control (no message) REF – REF –
Direct SMS message 2.73 (1.74 – 4.26) <0.001 3.05 (1.73 – 5.35) <0.001
PIN SMS message 1.71 (1.12 – 2.61) 0.013 2.03 (1.20 – 3.45) 0.009
Coded SMS message 3.98 (2.38 – 6.65) <0.001 3.28 (1.85 – 5.65) <0.001
B. Outcome: Time to initiation of antiretroviral therapy after an abnormal CD4+ T-lymphocyte result
Univariable estimate Multivariable estimate
Characteristic HR (95 %CI) P-value AHR (95 %CI) P-value
Age (each year) 1.00 (0.98 – 1.02) 0.968 1.02 (1.00 – 1.04) 0.067
Female gender 0.99 (0.70 – 1.40) 0.956 1.12 (0.77 – 1.63) 0.543
Educational attainment (Ref: primary or less) 0.78 (0.55 – 1.11) 0.169 0.71 (0.49 – 1.03) 0.073
Mbarara district resident 0.92 (0.65 – 1.32) 0.664 0.98 (0.68 – 1.44) 0.946
CD4 result (each 100 cells) 0.70 (0.59 – 0.83) <0.001 0.69 (0.58 – 0.82) <0.001
Study period
Control (no message) REF
Intervention (any message) 2.21 (1.40 – 3.47) 0.001 2.27 (1.38 – 3.72) 0.001
Study group
Control (no message) REF
Direct SMS message 2.24 (1.31 – 3.84) 0.003 2.40 (1.27 – 4.54) 0.007
PIN SMS message 1.91 (1.11 – 3.27) 0.018 2.36 (1.21 – 4.61) 0.011
Coded SMS message 3.54 (1.94 – 6.47) <0.001 3.06 (1.61 – 5.84) 0.001
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Other strategies that have been proposed to improve
linkage to and retention in care include decentralization of
HIV services [30, 31], incorporation of HIV care into
primary care programs [32], eliminating requirements
for additional pre-therapy counseling visit [33], and
provision of transportation stipends to minimize patient
costs of care [34]. Given the complex and population-
specific array of factors contributing to poor retention
rates across the continent, it is likely that a combin-
ation of interventions will be required to overcome the
widespread epidemic of program loss in sub-Saharan
Africa [35].
Our findings also provide support for use of patient-
centered, mHealth-based applications to improve health
care delivery in similar settings, for which prior efficacy
data is limited [36]. The intervention studied here is
among the first patient-centered, mHealth intervention
to improve patient-provider clinical communication for
HIV care in a resource-limited setting. In contrast, prior
mHealth evaluations for HIV care delivery have either
relied on health care workers as the end users, as opposed
to patients themselves [27, 37], or focused on notifications
to improve adherence [18, 19, 38]. Two characteristics of
our combination intervention should be considered for
future mHealth interventions for low-literacy end users.
First, as described in the Methods section, we designed
the intervention in response to a conceptual framework
explaining the health problem of interest. Preliminary
work identified a combination of poor communication
and financial constraints as primary barriers to return to
clinic after abnormal test results, and our combination
intervention leveraged the regional mobile health infra-
structure and a transportation reimbursement to address
both simultaneously.
Fig. 2 Kaplan-Meier plots demonstrating days from abnormal CD4 count result until return to clinic (a) and days from abnormal CD4 count result
until ART initiation (b). The left panels compare results for participants in the pre-intervention period (control) versus all participants in the intervention
period (SMS). The right panels compare results between the pre-intervention period (control) and each of the three randomized SMS message groups
(direct, PIN, and coded)
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The second factor supporting success of the intervention
was use of a co-creation model of development, through
partnership with local stakeholders (that is, clinical staff)
and targeted end users, during application design, evalu-
ation, and implementation [22]. Important lessons were
derived from this process, which undoubtedly prevented a
substantial proportion of communication failures. For
example, pre-intervention surveys revealed that patients at
the clinic overwhelmingly supported an SMS-based sys-
tem to improve clinical communication, but also that
an important minority were concerned about breaches
in confidentiality. In response to this input, we selected
a randomized design of three message formats, interchan-
ging clarity through direct messages with privacy through
coded and PIN-protected messages. While piloting the
intervention, we also learned that use of the number “1” is
restricted on many Ugandan mobile phones, and so we re-
moved this option from all PIN numbers and response
functions during the intervention stage.
Our study is subject to a number of limitations. First,
we implemented an unblinded, non-randomized study
design, and found differences in the study periods in
participant age and proportion naïve to ART. While the
differences in time to clinic return and time to ART ini-
tiation could be explained by unmeasured confounders
or temporal changes in clinic outcomes, we believe this
is unlikely because 1) our results were independent of
the most likely confounding variables, including immune
status, gender, and education, 2) our effect sizes were large
and demonstrated across all randomized subgroups, and 3)
the intervention period immediately followed the control
period and no other changes in clinical protocols took place
during either period. Second, our study was implemented
within a research setting. Effectiveness studies should be
pursued to evaluate its impact on a larger, real-world scale.
In its current format, our intervention requires a single
phone and/or Internet connection, a staff member to
process and enter results, and the cost of a transportation
stipend ($6 per patient in our case). These inputs are com-
parable to the cost, infrastructure, and human resources
requirements for standard point-of-care CD4 tests, which
require similar resources and cost approximately $10 per
sample. While the greatest threat to sustainability of our
intervention is the cost of the transportation reimburse-
ment, it is likely that this could be a one-time cost for
most patients. Data from our site and others has demon-
strated that economic restoration is rapid and largely
complete during the first year of ART therapy, suggesting
the potential to decrease reliance on economic support
early after initiation of care [39, 40]. While not imple-
mented in our study design, the automation of financial
incentives could be an important addition to this platform
with the use of a “mobile money” platform (that is, auto-
matic transfer of money through a mobile phone account).
Lastly, we developed and tested a combination intervention;
thus, we cannot assess whether the impact we detected
was a result of either intervention alone or the combin-
ation of the two. However, we developed the combination
intervention in response to a conceptual framework de-
rived from formative research noting both financial and
communication barriers to care, and thus posited that
both were needed to meaningfully impact care. For ex-
ample, a transportation reimbursement for early clinic
return would be of little benefit in the absence of a no-
tification system to alert patients of the need for early
return. An important area of future study will be to
identify the independent effects of the SMS messaging
component with and without a transportation stipend.
Conclusions
In summary, we found significant improvements in time
to clinic return and ART initiation after abnormal labora-
tory results in southwestern Uganda with an SMS-based
combination intervention including laboratory result notifi-
cations and transportation reimbursements. The benefit of
the intervention was seen in three different SMS formats
with varying degrees of clarity and confidentiality. Future
investigations should evaluate the scalability of similar
interventions. Successful reproducibility would add a prom-
ising strategy to improving HIV care in sub-Saharan Africa.
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